The Largest Personal Injury Firm in Texas. Serving Clients Nationwide.
Corpus Christi 361-985-0600 San Antonio 210-656-1000 Nationwide Toll Free 888-314-9945
Contact us 24/7

Reports of Fatal Bleeding in Pradaxa Patients

Pradaxa (dabigatran) is a blood thinning (anticoagulant) drug approved to prevent blood clotting and strokes in patients with atrial fibrillation (abnormal heart rhythm). Since its approval in 2010, Pradaxa manufacturer Boehringer Ingelheim has received hundreds of reports of fatal bleeding in patients taking the drug, including several cases ending in death. The Food and Drug Administration (FDA) is currently investigating these reports.


  • Abnormal bleeding
  • Blood in vomit, urine, or stool
  • Ulcers (digestive tract)
  • Indigestion/heartburn
  • Abdominal paint or discomfort
  • Cerebral hemorrhaging
  • Life-threatening internal bleeding


A recent study, conducted by doctors at the Cleveland Clinic and published in the Jan. 9 issue of Archives of Internal Medicine, found that Pradaxa boosted the risk of a heart attack and acute coronary syndrome by 33% when compared to alternate therapies. The study involved more than 30,000 people taking either Pradaxa, warfarin, enoxaparin, or a placebo..


Contact us for a free case review

888-314-9945 •